Longevity research: exposure, biomarkers and useful outcomes

Updated 10 Oct 2026

The interesting frontier includes mitochondrial signals, telomere biology and NAD metabolism. It also includes a recurring trap: finding a molecule involved in aging, changing a related measurement, then assuming that health or lifespan has improved. The missing step is an outcome experiment. Some human studies have supplied encouraging signals; several larger or longer studies have not supported the broader expectation.

MOTS-c: exercise biology is not an injection trial

MOTS-c is a mitochondrial-derived peptide. An original study connected it to physical capacity and muscle adaptation in mice, and found that exercise increased the body’s own MOTS-c in human muscle and circulation. The human part did not establish that administering MOTS-c improves fitness. A naturally changing signal can be a marker, a mediator or both; giving extra material is a separate intervention. Original exercise and aging investigation

FDA’s July 2026 evaluation did not identify clinical studies establishing the safety or effectiveness of administered native MOTS-c. It also highlights uncertainty about active exposure, including rapid degradation in human blood in an in-vitro experiment. This is a development question, not proof that the molecule could never work or that every exposure is toxic. FDA MOTS-c evaluation

CB4211 is a modified candidate, with preliminary human data

CohBar developed CB4211 from MOTS-c; the company describes it as a distinct investigational candidate. Its completed Phase 1a/1b registration records 88 participants across the study, with no results posted in the registry. The smaller Phase 1b outcome group should not be mistaken for all 88 participants. Official trial registration, Sponsor’s original development filing

The sponsor’s August 2021 report described four-week findings in 11 treated participants and 9 receiving placebo with obesity and fatty liver. Liver-enzyme and glucose signals favored CB4211; body weight showed a trend, and liver fat fell substantially in both groups. These were exploratory sponsor-reported results, not a demonstrated prevention of liver disease or a lifespan outcome. The same development record documents earlier injection-site reactions that temporarily suspended the program before it resumed. Original sponsor results filed with the SEC

A newer native-name MOTS-c record describes a planned Phase 2a study, but has no posted results. It belongs to the same sponsor cluster discussed in the recovery-peptide investigation, whose entries include an explicitly fictional and a mock study. That association raises a verification problem; it does not independently prove that every related entry is false. I do not count this registration as established human benefit or independently verified recruitment. Official MOTS-MET record

Epitalon and epithalamin are different materials

Epitalon, also called epithalon or AEDG, is a four-amino-acid peptide. Epithalamin is a pineal-gland extract containing a mixture of polypeptides. FDA explicitly distinguishes them. The human mortality paper often used in longevity discussions studied Thymalin and Epithalamin in older people, rather than establishing that the synthetic AEDG tetrapeptide prolonged human life. Even before assessing that older study’s methods, the identity mismatch prevents transferring its conclusion directly. FDA identity and clinical evaluation, Original 2003 human report

There is some direct human epitalon work; describing the entire evidence base as zero human studies would be inaccurate. An older mixed animal-and-human report described favorable retinal findings in people with retinitis pigmentosa. A later study examined melatonin-metabolite and circadian-gene measurements in middle-aged night-shift workers. These are distinct populations, routes and outcomes from generalized rejuvenation. Original retinal report, Original circadian-biomarker report

FDA’s detailed account of the latter study identifies 75 women screened into a reference group and two randomized groups of 20 with low melatonin-metabolite excretion. The metabolite increased about 1.7-fold with sublingual AEDG, but sleep outcomes were not assessed. Related gene-expression reports should not be counted as independent replication unless cohort independence is established. A changed melatonin measurement therefore does not establish treatment of insomnia, much less slower aging. FDA clinical-evidence assessment

A 2025 original experiment extended telomeres in cultured normal cells and cancer cell lines, using different pathways. These are cells in a laboratory, not people with measured longer lives. The cancer-cell result also makes it inappropriate to treat telomere extension as an automatically favorable outcome. It does not prove that epitalon causes cancer in humans; that clinical risk has not been quantified by this experiment. Original cell-line investigation

NR and NMN are NAD precursors, not peptides

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) belong to a different chemical category. Their human literature is more substantial than the direct native-MOTS-c evidence. Even here, raising NAD-related metabolites and improving a clinical outcome remain separate claims.

A ten-week randomized NMN study in overweight or obese postmenopausal women with prediabetes found improved insulin-stimulated glucose disposal and muscle insulin signaling. That is a useful, specific metabolic finding. It is not evidence that a healthy young adult will recover faster from training or live longer. Original prediabetes trial

A 2022 study of older men reported nominal improvements in gait speed and left-hand grip. Forty-two men were randomized, but a supply error switched treatments for 22 after six weeks, whose twelve-week data were excluded. Multiple exploratory comparisons were not corrected. The signal merits investigation, with those limitations attached. Original older-men trial

The September 25, 2026 follow-up research question has a less encouraging outcome. A separate 24-week high-dose trial randomized 62 older adults, with 60 in its efficacy analysis. Circulating NAD-related metabolites increased substantially, while hearing—the primary endpoint—and physical performance did not improve. Nominal body-composition and other findings did not survive correction for multiple comparisons. This is new evidence for sustained biological exposure, with limited broader functional benefit. It is not a high-dose recommendation. Original 2026 trial, accepted article in press

A useful walking signal, with a less conventional statistical threshold

In the NICE study, 90 people with peripheral artery disease were randomized to NR, NR plus resveratrol, or placebo. NR alone improved six-minute walking distance by an estimated 17.6 metres relative to placebo at six months. The trial used a prespecified one-sided significance threshold of 0.10 and a one-sided 90% interval, a more permissive standard than the commonly reported two-sided 0.05 test. The pooled NR-containing groups did not significantly improve that six-month outcome. Resveratrol did not add an established benefit. The result is a promising disease-specific functional signal that needs confirmation, rather than a general endurance claim. Original NICE trial

The larger Parkinson trial changed the early story

The 2022 NADPARK Phase I trial enrolled 30 newly diagnosed, untreated people with Parkinson disease. NR raised cerebral NAD variably, with exploratory metabolic and mild clinical signals among participants showing a brain-NAD response. Its appropriate implication was to test the hypothesis further. Original NADPARK study

NOPARK, published October 8, 2026, did not confirm a clinical benefit. It randomized 410 people with early Parkinson disease; 393 entered the primary-analysis population, and 391 contributed valid baseline scores to the primary outcome model. At 52 weeks the clinical-score difference was 2.72 points favoring placebo (95% CI 0.47–4.98). This mean difference was smaller than the cited 5.2-point threshold for clinically important worsening; the trial used a 5-point difference for sample-size planning. Serious adverse events were numerically less frequent with NR, but the event-rate difference was not statistically significant. The result does not establish greater serious toxicity, or disease modification from the earlier pilot. Original NOPARK randomized trial

A separate 2026 NAD-brain experiment adds pharmacokinetic information: blood and brain NAD responses were gradual and variable, in a small group of healthy participants and people with Parkinson disease. Exposure measurements help design trials. They do not reverse NOPARK’s clinical result, and they do not establish a personal NAD target or supplementation schedule. Original NAD-brain study

Product status and outcome evidence should stay separate

FDA reversed its earlier drug-exclusion position for NMN in its September 29, 2025 petition response, concluding that NMN was not excluded from the dietary-supplement definition under that provision. This is a regulatory classification decision, not approval of anti-aging efficacy or every marketed product. FDA does not approve dietary supplements for safety and effectiveness before marketing. FDA petition response, FDA supplement questions and answers

Oral precursor studies also should not be used to justify intravenous NAD products. FDA has specifically warned about unsuitable food-grade NAD ingredients used in sterile compounding, because microbial and endotoxin contamination can harm patients. Identity, route and preparation remain consequential. FDA sterile-compounding notice

What belongs on my watch list?

The useful next studies measure outcomes in a defined population: confirmed walking benefit in peripheral artery disease, reproducible metabolic effects, or a demonstrable recovery or disease outcome. None of the selected human experiments here demonstrated a longer lifespan. For my present food-and-training decisions, these findings create research questions rather than a reason to add experimental substances to the daily diet or the recovery plan.

Back to investigations